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ABSTRACT 
Objective: Ocular infections caused by Multi-Drug resistant (MDR) Pseudomonas aeruginosa are rare but increasingly identified recently. In this 
context, we have applied Next Generation Sequencing (NGS) based whole genome analysis on three ocular isolates of MDR P. aeruginosa to explore 
the drug resistance determinants and genomic level variations.  
Methods: Three ocular isolates namely P. aeruginosa VRFP03, VRFPA04 from two different Keratitis patients (corneal button) and VRFPA05 
isolated from the intraocular specimen (Vitreous humor) collected from an endophthalmitis patient was included in this study. Phenotypically 
VRFPA03, VRFPA04, VRFPA05 showed resistant to a wide group of antibiotics and hence they were taken up for Ion Torrent-PGM based whole 
genome study. 
Results: Here, we report the first complete genome sequence of MDR P. aeruginosa VRFPA04 isolated from the Indian keratitis patients clinical 
specimen (corneal button) submitted to L & T Microbiology Research Centre, Vision Research Foundation, Sankara Nethralaya, Chennai, Tamil 
Nadu, India. The circular chromosome of P aeruginosa VRFPA04 was published under the NCBI accession number CP008739.2. Two Draft genome 
sequences of MDR P. aeruginosa VRFPA03 and VRFPA05 were published under the NCBI accession number ATNK01000000.1 and AXZJ01000000.1 
respectively. 
Conclusion: Preliminary genomic analysis on P. aeruginosa VRFPA03, VRFPA04 and VRFPA05 revealed the presence of Metallo Beta-lactamase 
(MBL) genes blaDim-1, blaVim-2 and blaGes-9 genes respectively. These MBL genes were concordance with a phenotypic pattern of carbapenem 
resistance among VRFPA03, VRFPA04 and VRFPA05 strains, respectively. We are proud to share that this is the first of its kind to report bla DIM-1 
from an Indian 
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isolate especially from an Ocular origin. 
 
Pseudomonas aeruginosa (P. aeruginosa) is an important nosocomial, 
gram-negative, opportunistic pathogen infecting immuno-
compromised humans. P. aeruginosa contributes to a significant 
proportion of bacterial keratitis, accounting for 6–39% of the cases 
in the United States and 8–21% in South India [1, 2]. Contact lens 
wearers were more prone to get P. aeruginosa infection due to the 
ubiquitous nature of the bacterium, and it is a common contaminant 
of contact lens cases leading to ocular infections [3]. Occasionally, 
severe Pseudomonas keratitis can invade intraocular tissues either 
by infection or by trauma, resulting into endophthalmitis, a sight-
threatening condition [4]. The presence of the multidrug-resistant 
(MDR) P. aeruginosa in patients with ocular infections seems to be 
increasing in consonance with the increase of drug resistance among 
systemic bacterial infections [5].  
In this context, we report the first complete genome sequence of 
multidrug-resistant (MDR) Pseudomonas aeruginosa VRFPA04 from 
India, and two draft genome sequence of P. aeruginosa VRFPA03 and 
VRFPA05. P. aeruginosa VRFP03 and VRFPA04 were isolated from 
two different keratitis patients (corneal button) and VRFPA05 was 
isolated from vitreous humor sample of a patient clinically 
suspected with postoperative endophthalmitis. Phenotypically, P 
aeruginosa VRFPA03, VRFPA04 and VRFPA05 exhibited higher 
resistant to almost all commonly used drugs, including 
carbapenems, except aztreonam and colistin. Whereas, VRFPA03 
and VRFPA05 were additionally susceptible to imipenem drug 
confirmed by Minimum inhibitory Concentration (MIC) and 
standard Kirby-Bauer methods [6-8]. Hence, they were taken up for 
whole genome sequencing using in-house Ion Torrent (PGM) 
sequencer with 400-bp read chemistry (Life Technologies). The 
Sequencing protocol was followed as per previous report [9-11] and 
it produced 2.3 million reads (2,369,461) [VRFPA03], 2.6 million 
reads (2,631,848) [VRFPA04] and 1.8 million reads (1,895,953) 
[VRFPA05] respectively under optimal parameters. The best-
assembled result using optimal parameter produced 150, 80 and 
170 contigs with 46x, 81X and 65x genome coverage, for VRFPA03, 
VRFPA04 and VRFPA05 genome respectively. Whole genome 
sequence length of 7,037,729 bp, 6,998,695 bp and 7,050,363 bp for 
VRFPA03, VRFPA04 and VRFPA05 respectively was obtained and 
they were submitted and published in NCBI under the draft genome 
accession no ATNK01000000.1, AWWZ01000000.1. and 
AXZJ01000000.1 respectively. 
Since, VRFPA04 genome resulted in lowest contig number and its 
highly drug-resistant comparable to VRFPA03 and VRFPA05, it was 
chosen for genome finishing. Enrichment of VRFPA04 draft genome 
sequences by Mauve analysis yielded 78 contigs and the gaps 
between 78 contigs were closed by designing 77 set of primers using 
CLC Genomics Workbench-Genome Finishing module software 
version 6.5.1 (CLC bio, Germantown, MD) and the gaps were filled in 
as per earlier report [7]. The assembled data was subjected to RAST 
annotation [12] and Prokaryotic Genome Automatic Annotation 
Pipeline (PGAAP). Closing the gaps of VRFPA04 draft genome with 
additional parameters yielded a circular complete chromosome of 
6,818,030 bp (6.8 Mb) genome size were the first of its kind to 
report from India on complete circular chromosome of MDR P. 
aeruginosa and published under the NCBI accession no CP008739.2, 
which happen to be the third largest complete genome available in 
the Genbank to date. Complete genome sequence of P. aeruginosa 
VRFPA04 published in NCBI on 21st August 2014 and it was 
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considered as the largest genome available in the NCBI as on august 
2014. P. aeruginosa strain Carb01-63 (CP011317.1) and P. 
aeruginosa NCGM1984 (AP014646.1) (unpublished data) was now 
considered as the two largest genome published in NCBI after 
VRFPA04. Despite, draft genomes with more than 6.8Mb are 
available, they were incomplete and the higher genome size may be 
due to duplication of same regions covered multiple times during 
the process. In our study, duplicate sequences were trimmed during 
the analysis of complete genome process of VRFPA04. PGAAP 
annotation deciphered, P. aeruginosa VRFPA04 chromosome 
consisted of 5,939 protein-encoding genes (excluding 64 
pseudogenes), 5,778 coding sequences (CDS), 69 tRNA genes, 27 
rRNA genes, and 1 noncoding RNA. Whereas P. aeruginosa VRFPA03 
and VRFPA05 comprised of 5,973 and 6,155 protein-coding genes, 
with 57 and 66 tRNA genes followed by 5 and 18 ribosomal 
encoding rRNA genes, respectively. Three non-coding RNAs 
(ncRNAs) were found in the VRFPA03 genome and no ncRNAs were 
found in the VRFPA05 genome. Identity of the strains were 
confirmed by in silico multilocus sequence typing (MLST) 
(http://cge. cbs. dtu. dk/services/) using the Pseudomonas 
aeruginosa MLST database targeting seven potential loci (acsA, aroE, 
guaA, mutL, nuoD, ppsA, and trpE) and classified the P. aeruginosa 
VRFPA03 as novel unknown sequence type and VRFPA04 under 
(ST)-823 and VRFPA05 under ST-1203. The preliminary genome-
wide analysis of drug resistance mechanism using Resfinder tool 
[13] predicted the presence of novel blaDim-1 in VRFPA03 genome, 
which is the first of its kind to report of this (blaDim-1) Dutch 
imipenamase gene from India, especially from an ocular isolate. 
Whereas blaVim-2 gene identified from VRFPA04 and blaGes-9 from 
VRFPA05 defend 
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the MDR mechanism of resistance against 
cephalosporins and carbapenem drugs. Further, in-depth analysis of 
these strains will be carried out and published in near future. 
Nucleotide sequence accession numbers. The complete Genome 
Sequence of P. aeruginosa strain VRFPA04 has been deposited at 
DDBJ/EMBL/GenBank under accession CP008739.2 and the draft 
genome sequence of VRFPA03, VRFPA04, and VRFPA05 has been 
deposited at DDBJ/EMBL/GenBank under accession no. 
ATNK01000000.1, AWWZ01000000.1. and AXZJ01000000.1 
respectively.  
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